PHARMACEUTICAL DRUGS DRUG TREATMENTS

Brand Owner (click to sort) Address Description
ONCARES Resverlogix Inc. 202, 279 Midpark Way S.E. Calgary T2X 1M2 Canada PHARMACEUTICAL DRUGS AND DRUG TREATMENTS, AND INFORMATIONAL MATERIALS TO ASSIST IN THE TREATMENT AND UNDERSTANDING OF CANCER;THE DEVELOPMENT, MANUFACTURE, ADMINISTRATION, SALE AND DISTRIBUTION OF PHARMACEUTICAL DRUGS AND DRUG TREATMENTS, AND INFORMATIONAL MATERIALS RELATING TO THE TREATMENT AND UNDERSTANDING OF CANCER;
RETIGEN Resverlogix Corp. 300, 4820 Richard Road SW Calgary, AB T3E 6L1 Canada PHARMACEUTICAL DRUGS AND DRUG TREATMENTS, AND INFORMATIONAL MATERIALS TO ASSIST IN THE TREATMENT AND UNDERSTANDING OF OCULAR DISEASE, INCLUDING MACULAR DEGENERATION AND DIABETIC RETINOPATHY; AND ITS SIDE EFFECTS;THE DEVELOPMENT, MANUFACTURE, ADMINISTRATION, SALE AND DISTRIBUTION OF PHARMACEUTICAL DRUGS AND DRUG TREATMENTS, AND INFORMATIONAL MATERIALS RELATING TO THE TREATMENT AND UNDERSTANDING OF OCULAR DISEASE, INCLUDING MACULAR DEGENERATION AND DIABETIC RETINOPATHY; AND ITS SIDE EFFECTS;
 

Where the owner name is not linked, that owner no longer owns the brand

    
Technical Examples
  1. The invention is directed to an implantable device to enable delivery of drugs to the retina. The device minimizes stress to the retina by virtue of its softness and smooth shape that conform to the retina. Drugs are delivered by osmosis or by the device dissolving. It may be connected to an externally mounted pump and drug reservoir that control the amount of drug. It contains one or more holes that are positioned to deliver drugs to the desired location. Drugs may stimulate the retina to enable vision in blind patients. Drugs may be injected directly inside the eye by a trans-scleral pump and valve drug delivery device.